Sleep Cycle Q1 2025: Sales and EBIT in line, subscriber softness persists

Research Note

2025-04-25

08:06

Sleep Cycle delivered a Q1 report that was broadly in line with our expectations on both sales and EBIT, despite continued subscriber headwinds. The muted topline and subscriber growth reflect persistent weakness in the broader sleep health category on the App Store. However, we view the quarter as solid given Sleep Cycle’s ability to gain market share from competitors, highlighting strong product-market fit and execution.

Jessica Grunewald

Initial comment

Sleep Cycle Q1: Estimates versus Actual
Q1'25eQ1'25aQ1'24aDiff vs estimates
Subscribers919904893-2%
Growth y/y (%)3%1%
ARPU2722722760%
Growth y/y (%)-1%-1%
Net sales666564-2%
Growth y/y (%)4%2%
EBIT1717140%
(%)26%26%22% 0pp
Source: Sleep Cycle, Redeye Research

Muted topline growth as expected – subscriber softness partly offset by market share gains

Sleep Cycle reported Q1 2025 net sales of SEK65m, corresponding to year-on-year growth of 2.3% (1.6% currency-adjusted), broadly in line with our estimate of ~SEK66m (2% below).

The paying subscriber base declined sequentially to 904k (918k in Q4 2024), 2% below our forecast of 919k. Management attributes the decline of 14,000 subscribers to softer market conditions and lower new customer acquisition during the quarter. ARPU came in at SEK272 (SEK270 FX-adjusted), in line with our expectations and down slightly y/y (SEK276 in Q1 2024).

CEO Erik Jivmark highlighted the continued volatility in market conditions that began in late 2024, with a general decline in the sleep health segment on the App Store weighing on the industry. Notably, however, he emphasised that Sleep Cycle gained market share during the quarter, underlining the strength of the product and brand in a contracting market.

Profitability in line – strategic investments weigh on margin

Disclosures and disclaimers